Abstract: Nucleic acid expression systems for delivery of RNA oligonucleotides to target cells and methods of using the same are provided herein. For example, in some embodiments, a nucleic acid expression system comprises: (i) an RNA oligonucleotide comprising a payload sequence (e.g., a Myc inhibitor), and (ii) an RNA oligonucleotide comprising a sequence that encodes a US11 polypeptide. Provided herein are also pharmaceutical compositions comprising an RNA oligonucleotide comprising a payload sequence that encodes a dominant negative variant of a Myc polypeptide or portions thereof, and a pharmaceutically acceptable carrier.

Abstract: The present disclosure provides technologies for MYC inhibition, including, e.g. MYC fusion polypeptides and compositions comprising the same as well as methods of using the same. In particular, the present disclosure, among others, provides fusion polypeptides comprising a mutant MYC polypeptide and a repressor domain. In some embodiments, such fusion polypeptides and compositions comprising the same can be useful for inducing cancer cell apoptosis. Accordingly, in some embodiments, such fusion polypeptides and compositions comprising the same can be useful for cancer treatment.

Abstract: Nucleic acid expression systems are provided herein that include a first synthetic oligonucleotide comprising a payload sequence and a second synthetic oligonucleotide comprising a sequence that encodes a helper polypeptide. Compositions (e.g., pharmaceutical compositions) comprising the nucleic acid expression systems as well as methods of using the same are also provided herein.

Abstract: Linear covalently closed vectors, and compositions and methods for making same.

Abstract: The present invention relates to mutants of Cre recombinase.

Abstract: The present invention relates to mutants of Cre recombinase.

Abstract: Methods and compositions for synthesizing nucleic acid sequences of interest from heterogeneous mixtures of oligonucleotide sequences are provided.